503b semaglutide Flex Certified FDA Ends Compounded GLP-1s: What

eligibility criteria included adults with a BMI of 35 or above, at least 1 year of prior health care exposure, and no prior cancer or preexisting high risk for death

60 These findings are supported by additional observational and real-world cohort studies demonstrating similar pancreatitis rates among patients treated with GLP-1 RAs and those receiving other glucose-lowering therapies

In the first head-to-head trial, SURMOUNT-5, tirzepatide produced greater average weight loss than semaglutide (20.2% vs 13.7% at 72 weeks) with fewer gastrointestinal discontinuations, yet the switch still begins with a low tirzepatide dose and a structured escalation

Individual Results May Vary Responses to GLP-1 therapy can vary from person to person

3.4 Gastrointestinal Side Effects and Secondary Risk Nausea, vomiting and diarrhoea are most common during dose escalation

Then, seek legal advice from an attorney experienced in pursuing claims for dangerous medications